AGLE - Aeglea BioTherapeutics Inc Stock Price, Fair Value and News

27.60USD-0.08 (-0.29%)Delayed

Market Summary

USD27.60-0.08

Delayed

-0.29%

AGLE Stock Price

View Fullscreen

AGLE RSI Chart

AGLE Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-3.04

Price/Sales (Trailing)

1.3K

EV/EBITDA

-2.42

Price/Free Cashflow

-10

AGLE Price/Sales (Trailing)

AGLE Profitability

EBT Margin

-41104.18%

Return on Equity

-239.2%

Return on Assets

-74.7%

Free Cashflow Yield

-10%

AGLE Fundamentals

AGLE Revenue

Revenue (TTM)

886.0K

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

AGLE Earnings

Earnings (TTM)

-364.2M

Earnings Growth (Yr)

-138.07%

Earnings Growth (Qtr)

30.58%

Breaking Down AGLE Revenue

Last 7 days

14.0%

Last 30 days

51.4%

Last 90 days

158.0%

Trailing 12 Months

122.8%

How does AGLE drawdown profile look like?

AGLE Financial Health

Current Ratio

11.38

AGLE Investor Care

Shares Dilution (1Y)

1440.00%

Diluted EPS (TTM)

-46.08

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	1.2M	1.2M	1.1M	886.0K
2022	20.1M	7.0M	5.8M	2.3M
2021	5.5M	9.9M	14.3M	18.7M
2020	1.5M	1.7M	1.1M	0
2019	0	3.0M	1.2M	0
2018	5.7M	6.6M	5.4M	3.9M
2017	4.8M	4.9M	5.0M	5.2M
2016	6.9M	4.9M	5.0M	4.6M
2015	0	0	0	6.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Aeglea BioTherapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 24, 2023	fairmount funds management llc	acquired	-	-	3,435,480	-
Nov 24, 2023	turtle cameron	acquired	-	-	723,440	chief executive officer
Aug 25, 2022	souza marcio	bought	50,472	0.5608	90,000	-
Jun 08, 2022	hanley jr. michael conick	bought	20,022	0.71	28,200	chief commercial officer
Mar 16, 2022	quinn anthony g.	bought	187,705	2.344	80,079	president & ceo
Mar 15, 2022	quinn anthony g.	bought	78,942	1.8611	42,417	president & ceo
Mar 14, 2022	quinn anthony g.	bought	130,221	1.93	67,472	president & ceo
Mar 11, 2022	quinn anthony g.	bought	71,779	2.064	34,777	president & ceo
Mar 11, 2022	alspaugh jonathan	bought	156,000	2.08	75,000	chief financial officer
Dec 13, 2021	shanafelt armen	bought	53,600	3.65	14,685	-

Which funds bought or sold AGLE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	new	-	675,268	675,268	-%
May 16, 2024	JANE STREET GROUP, LLC	new	-	273,475	273,475	-%
May 15, 2024	Schonfeld Strategic Advisors LLC	new	-	1,346,520	1,346,520	0.01%
May 15, 2024	EcoR1 Capital, LLC	sold off	-100	-19,089,900	-	-%
May 15, 2024	Virtus ETF Advisers LLC	reduced	-6.43	87,172	221,435	0.12%
May 15, 2024	Ghost Tree Capital, LLC	new	-	3,793,000	3,793,000	1.05%
May 15, 2024	Boxer Capital, LLC	unchanged	-	4,102,500	9,482,500	0.47%
May 15, 2024	RTW INVESTMENTS, LP	unchanged	-	36,639,600	84,688,600	1.25%
May 15, 2024	Tower Research Capital LLC (TRC)	added	48.37	89,674	145,196	-%
May 15, 2024	Cubist Systematic Strategies, LLC	added	88.54	1,307,300	1,870,050	0.01%

Are Funds Buying or Selling AGLE?

Are funds buying AGLE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AGLE

No. of Funds

Unveiling Aeglea BioTherapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 25, 2024	fairmount funds management llc	9.99%	4,024,541	SC 13D/A
Apr 23, 2024	avoro capital advisors llc	5.1%	1,839,138	SC 13G/A
Mar 11, 2024	fmr llc	-	0	SC 13G/A
Feb 14, 2024	commodore capital lp	5.4%	1,934,084	SC 13G/A
Feb 14, 2024	deep track capital, lp	6.03%	2,184,440	SC 13G/A
Feb 14, 2024	venrock healthcare capital partners iii, l.p.	9.99%	3,734,514	SC 13G/A
Feb 14, 2024	logos global management lp	0.4%	150,000	SC 13G/A
Feb 14, 2024	avoro capital advisors llc	5.9%	2,125,597	SC 13G
Feb 14, 2024	rock springs capital management lp	0%	0	SC 13G/A
Feb 14, 2024	ecor1 capital, llc	2.5%	887,076	SC 13G/A

Recent SEC filings of Aeglea BioTherapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 16, 2024	3	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 15, 2024	424B3	Prospectus Filed
May 15, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report

Peers (Alternatives to Aeglea BioTherapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Aeglea BioTherapeutics Inc News

Latest updates

Aeglea BioTherapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q3	2020Q2	2020Q1	2019Q3	2019Q2	2018Q4	2018Q3	2018Q2
Revenue	-	-	-	-	688,000	198,000	168,000	174,000	625,000	1,362,000	3,644,000	1,399,000	13,696,000	6,892,000	88,000	161,000	300,000	585,000	619,000	12,000	-	2,378,000
Operating Expenses	4.1%	47,774,000	45,914,000	18,337,000	159,934,000	19,004,000	19,330,000	18,929,000	23,048,000	25,803,000	24,086,000	21,692,000	20,401,000	18,209,000	18,123,000	21,560,000	19,022,000	22,146,000	18,622,000	15,305,000	12,243,000	12,048,000
S&GA Expenses	-100.0%	-	14,072,000	8,584,000	12,062,000	5,228,000	5,079,000	6,952,000	7,675,000	8,825,000	7,304,000	6,839,000	6,822,000	6,354,000	5,672,000	4,691,000	4,460,000	4,307,000	3,816,000	3,507,000	3,314,000	2,926,000
R&D Expenses	-	-	-	-	-	13,776,000	14,251,000	11,977,000	15,373,000	16,978,000	16,782,000	14,853,000	13,579,000	11,855,000	12,451,000	16,869,000	14,562,000	17,839,000	14,806,000	11,798,000	8,929,000	9,122,000
EBITDA Margin	-7.6%	-410	-381	-278	-220	-65.61	-35.38	-14.47	-12.21	-3.50	-3.66	-4.62	-6.80	-	-	-	-	-	-	-	-	-
Income Taxes	-	32,000	-	3,000	7,000	-36,000	51,000	-209,000	9,000	-	23,000	26,000	92,000	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	30.6%	-43,825,000	-63,180,000	-40,104,000	-217,074,000	-18,458,000	-18,771,000	-18,443,000	-22,314,000	-24,436,000	-20,423,000	-20,281,000	-6,738,000	-	-18,033,000	-21,418,000	-	-	-	-	-	-
EBT Margin	-7.5%	-411	-382	-279	-222	-66.94	-36.05	-14.75	-12.44	-3.58	-3.74	-4.73	-6.93	-	-	-	-	-	-	-	-	-
Net Income	30.6%	-43,857,000	-63,180,000	-40,107,000	-217,081,000	-18,422,000	-18,822,000	-18,234,000	-22,323,000	-24,436,000	-20,446,000	-20,307,000	-6,830,000	-18,218,000	-18,033,000	-21,418,000	-18,728,000	-21,573,000	-18,019,000	-14,898,000	-11,917,000	-9,414,000
Net Income Margin	-7.5%	-411	-382	-279	-221	-66.78	-35.99	-14.72	-12.45	-3.58	-3.51	-4.75	-6.62	-	-	-	-	-	-	-	-	-
Free Cashflow	8.0%	-28,542,000	-31,036,000	-34,597,000	-16,643,000	-17,634,000	-18,140,000	-15,069,000	-20,673,000	-26,300,000	-19,268,000	-17,093,000	2,052,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	42.6%	488	342	207	244	52.00	71.00	92.00	107	83.00	110	129	147	164	162	156	173	65.00	83.00	100	117	129
Current Assets	42.7%	487	342	206	240	44.00	62.00	82.00	97.00	73.00	99.00	118	134	151	150	144	162	54.00	75.00	93.00	110	127
Cash Equivalents	20.6%	228	189	91.00	3.00	35.00	35.00	41.00	37.00	15.00	17.00	25.00	35.00	80.00	92.00	54.00	66.00	13.00	19.00	25.00	25.00	86.00
Net PPE	-	-	-	-	-	3.00	3.00	4.00	4.00	4.00	5.00	5.00	5.00	6.00	6.00	5.00	5.00	4.00	2.00	1.00	1.00	1.00
Liabilities	11.8%	82.00	73.00	66.00	254	19.00	21.00	24.00	23.00	22.00	26.00	27.00	28.00	40.00	22.00	19.00	21.00	22.00	23.00	20.00	18.00	12.00
Current Liabilities	33.9%	43.00	32.00	45.00	232	13.00	15.00	18.00	16.00	16.00	20.00	20.00	21.00	32.00	16.00	14.00	16.00	17.00	18.00	15.00	13.00	12.00
Shareholder's Equity	-17.3%	152	184	-	-	34.00	50.00	68.00	84.00	62.00	84.00	102	119	124	140	136	152	43.00	60.00	80.00	100	116
Retained Earnings	-5.7%	-808	-764	-701	-661	-444	-425	-406	-388	-366	-341	-321	-301	-294	-276	-253	-235	-213	-195	-173	-152	-134
Additional Paid-In Capital	1.7%	776	763	456	454	478	476	475	473	428	426	423	420	418	416	390	387	257	255	253	252	250
Shares Outstanding	1.6%	37.00	36.00	4.00	3.00	3.00	3.00	4.00	3.00	3.00	3.00	3.00	3.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	26.00	-	-	-	30.00	-	-	-	337	-	-	-	386	-	-	-	178	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	8.0%	-28,542	-31,036	-34,597	-16,643	-17,634	-18,140	-15,068	-20,673	-26,263	-19,268	-17,000	2,082	-19,530	-17,132	-17,536	-19,413	-21,694	-16,294	-17,208	-16,383	-15,807
Share Based Compensation	-20.1%	13,800	17,270	4,785	1,911	1,709	1,427	1,566	2,017	2,101	2,094	2,107	2,080	1,757	1,612	1,696	1,600	1,348	1,184	1,366	1,245	1,081
Cashflow From Investing	-197.6%	-104,963	-35,272	-97,631	6,760	17,750	14,000	16,499	750	25,759	9,663	5,777	-47,359	9,300	28,620	5,784	-56,761	14,753	10,326	16,012	-42,013	13,936
Cashflow From Financing	5.2%	172,165	163,606	-12,531	209,992	10.00	-8.00	-130	42,804	12.00	80.00	1,143	-192	362	24,679	258	129,293	282	676	311	-319	65,055

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AGLE Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2024

Mar. 31, 2023

Revenue:

Total revenue

$ 0

$ 198

Operating expenses:

Research and development

^[1]

34,928

13,776

General and administrative

12,846

5,228

Total operating expenses

47,774

19,004

Loss from operations

(47,774)

(18,806)

Other income (expense):

Interest income

4,432

420

Other expense

(483)

(72)

Total other income (expense)

3,949

348

Loss before income tax expense

(43,825)

(18,458)

Income tax (expense) benefit

(32)

Net loss

$ (43,857)

$ (18,422)

Net loss per share, basic (in dollars per share)

$ (1.20)

$ (4.89)

Net loss per share, diluted (in dollars per share)

$ (1.20)

$ (4.89)

Weighted-average common shares outstanding, basic (in shares)

36,512,662

3,770,506

Weighted-average common shares outstanding, diluted (in shares)

36,512,662

3,770,506

Development fee and royalty

Revenue:

Total revenue

$ 0

$ 198

[1]	Includes $17.1 million in related party expenses for the three months ended March 31, 2024 and no related party expenses for the three months ended March 31, 2023.

AGLE Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
CURRENT ASSETS
Cash and cash equivalents	$ 227,552	$ 188,893
Marketable securities	257,089	150,384
Prepaid expenses and other current assets	2,632	2,251
Total current assets	487,273	341,528
Restricted cash	319	322
Other non-current assets	10	9
TOTAL ASSETS	487,602	341,859
CURRENT LIABILITIES
Accounts payable	3,106	896
CVR liability	2,590	1,390
Accrued and other current liabilities	21,594	13,108
Related party accounts payable and other current liabilities	15,528	16,584
Total current liabilities	42,818	31,978
Non-current CVR liability	39,110	41,310
TOTAL LIABILITIES	81,928	73,288
Commitments and Contingencies (Note 6)
STOCKHOLDERS’ EQUITY
Common stock, $0.0001 par value; 400,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 36,629,680 shares and 36,057,109 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	10	10
Additional paid-in capital	775,966	763,191
Accumulated other comprehensive (loss) income	(363)	302
Accumulated deficit	(808,271)	(764,414)
TOTAL STOCKHOLDERS’ EQUITY	152,269	184,016
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY	487,602	341,859
Series B Non Voting Convertible Preferred Stock
CURRENT LIABILITIES
Series B non-voting convertible preferred stock, $0.0001 par value; $271,625 and $150,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively; $271,625 and $150,000 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	253,405	84,555
Series A Non Voting Convertible Preferred Stock
STOCKHOLDERS’ EQUITY
Series A non-voting convertible preferred stock & preferred stock shares authorized, issued, and outstanding, value	184,927	184,927
Preferred Stock, Excluding Series A Non Voting Convertible Preferred Stock
STOCKHOLDERS’ EQUITY
Series A non-voting convertible preferred stock & preferred stock shares authorized, issued, and outstanding, value	$ 0	$ 0

About Aeglea BioTherapeutics Inc

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

WEBSITE	aeglea.com
INDUSTRY	Biotechnology
EMPLOYEES	14

Aeglea BioTherapeutics Inc Frequently Asked Questions

What is the ticker symbol for Aeglea BioTherapeutics Inc? What does AGLE stand for in stocks?

AGLE is the stock ticker symbol of Aeglea BioTherapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aeglea BioTherapeutics Inc (AGLE)?

As of Tue Apr 30 2024, market cap of Aeglea BioTherapeutics Inc is 1.11 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AGLE stock?

You can check AGLE's fair value in chart for subscribers.

What is the fair value of AGLE stock?

You can check AGLE's fair value in chart for subscribers. The fair value of Aeglea BioTherapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aeglea BioTherapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AGLE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aeglea BioTherapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether AGLE is over valued or under valued. Whether Aeglea BioTherapeutics Inc is cheap or expensive depends on the assumptions which impact Aeglea BioTherapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AGLE.

What is Aeglea BioTherapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 30 2024, AGLE's PE ratio (Price to Earnings) is -3.04 and Price to Sales (PS) ratio is 1.25 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AGLE PE ratio will change depending on the future growth rate expectations of investors.